| Literature DB >> 31888157 |
Yu-Jing Liu1, Jian-Long Zhang1,2, Chen Li1, Xue-Gen Mu1, Xiao-Li Liu1, Lei Wang1, Yan-Cui Zhao1, Peng Zhang3, Xiao-Dong Li1,4, Xing-Xiao Zhang1.
Abstract
Marine-derived fungi are considered to be valuable producers of bioactive secondary metabolites used as lead compounds with medicinal importance. In this study, chemical investigation of the seawater-derived fungus Aspergillus sydowii SW9 led to the isolation and identification of one new quinazolinone alkaloid, 2-(4-hydroxybenzyl)-4-(3-acetyl)quinazolin-one (1), one new aromatic bisabolene-type sesquiterpenoid, (2) and one new chorismic acid analogue (3), as well as two known alkaloids (compounds 4 and 5). Their structures were determined by extensive 1D/2D NMR and mass spectrometric data, and the absolute configurations of 2 and 3 were assigned by the analysis of ECD spectra aided by quantum chemical computations. Compounds 1, 2, and 4 exhibited selective inhibitory activities against the human pathogenic bacteria Escherichia coli, Staphylococcus aureus, S. epidermidis, and Streptococcus pneumoniae, with MIC values ranging from 2.0 to 16 μg/mL.Entities:
Keywords: Aspergillus sydowii; antimicrobial activity; seawater-derived fungus; secondary metabolites
Mesh:
Substances:
Year: 2019 PMID: 31888157 PMCID: PMC6943586 DOI: 10.3390/molecules24244596
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1The structures of compounds 1–5 isolated from Aspergillus sydowii SW9.
1H and 13C data of compounds 1 and 2 (measured in DMSO-d6).
| 1 | 2 | ||||
|---|---|---|---|---|---|
| No. | No. | ||||
| 1 | - | - | 1 | - | 126.6, qC |
| 2 | - | 157.7, qC | 2 | - | 119.1, CH |
| 3 | - | - | 3 | 6.28, d (7.6) | 120.5, CH |
| 4 | - | 162.9, qC | 4 | 6.49, d (7.6) | 123.2, qC |
| 4a | - | 121.1, qC | 5 | - | 143.2, qC |
| 5 | 8.04, d (8.0) | 126.1, CH | 6 | - | 142.1, qC |
| 6 | 7.42, t (7.5) | 126.3, CH | 7 | - | 134.2, qC |
| 7 | 7.73, t (7.5) | 134.5, CH | 8 | 5.34, t (6.6) | 126.7, CH |
| 8 | 7.57, d (8.0) | 127.1, CH | 9 | 1.74, m | 26.3, CH2 |
| 8a | - | 149.5, qC | 10a | 1.54, m | 33.1, CH2 |
| 9 | 3.79, s | 40.7, CH2 | 10b | 1.33, m | - |
| 10 | - | 127.0, qC | 11 | 2.33, m | 38.0, CH |
| 11 | 7.14, d (7.8) | 130.2, CH | 12 | - | 176.1, qC |
| 12 | 6.70, d (7.8) | 115.7, CH | 13 | 0.94, d (6.6) | 16.1, CH3 |
| 13 | - | 157.0, qC | 14 | 1.88, s | 24.6, CH3 |
| 14 | 6.70, d (7.8) | 115.7, CH | 15 | 2.10, s | 16.5, CH3 |
| 15 | 7.14, d (7.8) | 130.2, CH | 1′ | 3.50, s | 51.1, CH3 |
| 1′ | - | 175.8, qC | |||
| 2′ | 1.67, s | 25.3, CH3 | |||
a Measured at 500 MHz; b Measured at 125 MHz.
Figure 2Key COSY (bold lines) and HMBC (red arrows) correlations for compounds 1–3.
Figure 3NOESY correlations (blue lines: β-orientation; blue dotted lines: α-orientation) of compounds 2 and 3.
Figure 4Experimental and calculated ECD spectra of compounds 2 (a) and 3 (b).
1H and 13C data of compound 3 (measured in DMSO-d6).
| No. | No. | ||||
|---|---|---|---|---|---|
| 1 | - | 129.4, qC | 1′′ | - | 109.5, qC |
| 2 | 6.71, s | 135.0, CH | 2′′ | 1.46, m | 37.7, CH2 |
| 3 | 4.71, s | 71.7, CH | 3′′ | 1.51, m | 24.0, CH2 |
| 4 | 4.16, t (6.2) | 75.1, CH | 4′′ | 1.31, m | 25.0, CH2 |
| 5 | 3.72, m | 75.5, CH | 5′′ | 1.48, m | 23.8, CH2 |
| 6a | 2.26, dd (6.5, 17.4) | 26.8, CH2 | 6′′ | 1.52, m | 35.4, CH2 |
| 6b | 2.46, dd (6.5, 17.4) | ||||
| 7 | - | 166.6, qC | 1′′′ | 3.63, s | 52.0, CH3 |
| 1′ | 4.23, m | 73.8, CH | 1′′′′ | 3.68, s | 52.5, CH3 |
| 2′ | - | 173.6, qC | |||
| 3′ | 1.22, d (6.8) | 19.5, CH3 |
a Measured at 500 MHz; b Measured at 125 MHz.
Antimicrobial activities of compounds 1–5 (MIC, μg/mL) a.
| Strains | 1 | 2 | 3 | 4 | 5 | Positive Control |
|---|---|---|---|---|---|---|
|
| 16 | 2.0 | – | 8.0 | – | 2.0 |
|
| 8.0 | 16 | – | 8.0 | 32 | 1.0 |
|
| 4.0 | 16 | 32 | 16 | – | 2.0 |
|
| 16 | 4.0 | 32 | 8.0 | 32 | 1.0 |
a (–) = MIC > 32 μg/mL, b Chloramphenicol as positive control.